Department of Microbiology, University of Manitoba, Winnipeg, Manitoba R3T2N2, Canada.
Department of Microbiology, University of Manitoba, Winnipeg, Manitoba R3T2N2, Canada.
Curr Opin Biotechnol. 2014 Dec;30:107-12. doi: 10.1016/j.copbio.2014.06.010. Epub 2014 Jul 5.
Non-human mammalian cells such as CHO have been used predominantly for the production of biopharmaceuticals including monoclonal antibodies (Mabs). Although the glycosylation profile of these products is 'human-like' there is still the possibility of immunogenic epitopes such as α-Gal and Neu5Gc. Human cell lines have now been designed for high productivity of recombinant proteins and ensuring authentic glycosylation patterns. The control of glycosylation on such proteins is important for the efficacy of recombinant biopharmaceuticals as well as the immunogenic properties of viral vaccines such as influenza. We are now starting to understand some of the relationships between the structure of glycans and the function bestowed on the associated protein. This has promoted cell culture technologies for the targeted control of glycosylation to produce pre-determined glycan profiles of secreted products.
非人类哺乳动物细胞（如 CHO）主要用于生物制药的生产，包括单克隆抗体（Mabs）。尽管这些产品的糖基化谱是“类似人类的”，但仍然存在免疫原性表位的可能性，如α-Gal 和 Neu5Gc。现在已经设计出了用于高产量生产重组蛋白的人细胞系，并确保了真正的糖基化模式。对这些蛋白质的糖基化控制对于重组生物制药的疗效以及流感等病毒疫苗的免疫原性特性都很重要。我们现在开始了解聚糖结构与赋予相关蛋白质的功能之间的一些关系。这促进了细胞培养技术的发展，以实现糖基化的靶向控制，从而产生预期的分泌产物的聚糖图谱。
